Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ADC Therapeutics (ADCT – Research Report) and TFF Pharmaceuticals (TFFP – Research Report) with bullish sentiments.

ADC Therapeutics (ADCT)

In a report released today, Naureen Quibria from Capital One Financial reiterated a Buy rating on ADC Therapeutics, with a price target of $10.00. The company’s shares closed last Thursday at $4.78.

According to TipRanks.com, Quibria is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -21.2% and a 22.9% success rate. Quibria covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Fennec Pharmaceuticals, and Olema Pharmaceuticals.

ADC Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.20, representing a 129.7% upside. In a report issued on March 28, Guggenheim also initiated coverage with a Buy rating on the stock with a $11.00 price target.

See the top stocks recommended by analysts >>

TFF Pharmaceuticals (TFFP)

JonesTrading analyst Justin Walsh maintained a Buy rating on TFF Pharmaceuticals today and set a price target of $13.00. The company’s shares closed last Thursday at $5.10, close to its 52-week low of $4.55.

According to TipRanks.com, Walsh is a 3-star analyst with an average return of 2.4% and a 34.0% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Perspective Therapeutics, and Fusion Pharmaceuticals.

TFF Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $24.50, a 375.7% upside from current levels. In a report issued on March 28, Roth MKM also maintained a Buy rating on the stock with a $44.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ADCT:

• ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
• ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
• ADC Therapeutics initiated with a Buy at Guggenheim
• JPMorgan biotech/pharma analysts hold an analyst/industry conference call
• ADC Therapeutics falls -13.5%